KR102884301B1 - 자궁 근종을 치료하고 월경혈량을 감소시키기 위한 고나도트로핀 방출 호르몬 길항제 투약 요법 - Google Patents

자궁 근종을 치료하고 월경혈량을 감소시키기 위한 고나도트로핀 방출 호르몬 길항제 투약 요법

Info

Publication number
KR102884301B1
KR102884301B1 KR1020197038980A KR20197038980A KR102884301B1 KR 102884301 B1 KR102884301 B1 KR 102884301B1 KR 1020197038980 A KR1020197038980 A KR 1020197038980A KR 20197038980 A KR20197038980 A KR 20197038980A KR 102884301 B1 KR102884301 B1 KR 102884301B1
Authority
KR
South Korea
Prior art keywords
delete delete
day
weeks
patient
days
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020197038980A
Other languages
English (en)
Korean (ko)
Other versions
KR20200024797A (ko
Inventor
어니스트 루메이
장-피에르 고테랜드
올리버 폴
Original Assignee
깃세이 야쿠힌 고교 가부시키가이샤
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 깃세이 야쿠힌 고교 가부시키가이샤 filed Critical 깃세이 야쿠힌 고교 가부시키가이샤
Publication of KR20200024797A publication Critical patent/KR20200024797A/ko
Application granted granted Critical
Publication of KR102884301B1 publication Critical patent/KR102884301B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Diabetes (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
KR1020197038980A 2017-06-05 2018-06-05 자궁 근종을 치료하고 월경혈량을 감소시키기 위한 고나도트로핀 방출 호르몬 길항제 투약 요법 Active KR102884301B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762515232P 2017-06-05 2017-06-05
US62/515,232 2017-06-05
PCT/EP2018/064767 WO2018224497A1 (en) 2017-06-05 2018-06-05 Gonadotropin-releasing hormone antagonist dosing regimens for treating uterine fibroids and reducing menstrual blood loss

Publications (2)

Publication Number Publication Date
KR20200024797A KR20200024797A (ko) 2020-03-09
KR102884301B1 true KR102884301B1 (ko) 2025-11-11

Family

ID=62636157

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020197038980A Active KR102884301B1 (ko) 2017-06-05 2018-06-05 자궁 근종을 치료하고 월경혈량을 감소시키기 위한 고나도트로핀 방출 호르몬 길항제 투약 요법

Country Status (18)

Country Link
US (2) US11759464B2 (enExample)
EP (2) EP4509173A3 (enExample)
JP (2) JP7292566B2 (enExample)
KR (1) KR102884301B1 (enExample)
CN (1) CN110996957A (enExample)
AU (2) AU2018280741B2 (enExample)
CA (1) CA3066188A1 (enExample)
DK (1) DK3634419T3 (enExample)
EA (1) EA201992812A1 (enExample)
ES (1) ES3018358T3 (enExample)
FI (1) FI3634419T3 (enExample)
HR (1) HRP20250390T1 (enExample)
HU (1) HUE070907T2 (enExample)
MX (2) MX2019014482A (enExample)
PL (1) PL3634419T3 (enExample)
PT (1) PT3634419T (enExample)
SG (1) SG11201911599XA (enExample)
WO (1) WO2018224497A1 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL241595B2 (en) 2013-03-15 2025-10-01 Abbvie Inc Composition for use in methods of treating heavy menstrual bleeding associated with uterine fibroids
EP3634418A1 (en) 2017-06-05 2020-04-15 ObsEva S.A. Gonadotropin-releasing hormone antagonist dosing regimens for the treatment of endometriosis
US11759464B2 (en) 2017-06-05 2023-09-19 Kissei Pharmaceutical Co., Ltd. Gonadotropin-releasing hormone antagonist dosing regimens for treating uterine fibroids and reducing menstrual blood loss
AU2018419533A1 (en) 2018-04-19 2020-11-12 Abbvie Inc. Methods of treating heavy menstrual bleeding
JP2021532160A (ja) * 2018-08-01 2021-11-25 アッヴィ・インコーポレイテッド エラゴリックスに関する投与計画
WO2020089190A2 (en) 2018-10-29 2020-05-07 ObsEva S.A. Compositions and methods for the treatment of adenomyosis and rectovaginal endometriosis
KR20210100623A (ko) * 2018-11-07 2021-08-17 옵스에파 에스에이 에스트로겐-의존성 장애의 치료를 위한 조성물 및 방법
US20220288154A1 (en) * 2019-08-08 2022-09-15 ObsEva S.A. Gnrh antagonists for the treatment of estrogen-dependent disorders
KR20220061120A (ko) * 2019-08-08 2022-05-12 옵스에파 에스에이 에스트로겐-의존성 장애 치료용 조성물 및 방법
KR20210155350A (ko) 2020-06-15 2021-12-22 한상왕 녹차 추출물 및 비타민 d3를 유효성분으로 포함하는 자궁근종 개선용 조성물
CN115232144B (zh) * 2021-04-22 2024-04-02 长春金赛药业有限责任公司 含氮稠环类衍生物、药物组合物及其制备方法和应用
KR102738115B1 (ko) 2024-03-25 2024-12-05 한상왕 자궁근종 예방, 개선 또는 치료용 약학 조성물

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7109171B2 (en) 2000-02-28 2006-09-19 Praecis Pharmaceuticals Inc. Methods for treating FSH related conditions with GnRH antagonists
PT1939204E (pt) * 2005-10-19 2013-03-14 Kissei Pharmaceutical Derivado heterocíclico fundido, composição medicinal contendo o mesmo, e sua utilização medicinal
EP2535342B1 (en) * 2010-02-10 2014-08-06 Kissei Pharmaceutical Co., Ltd. Salt of fused heterocyclic derivative and crystal thereof
JP6268093B2 (ja) 2012-09-14 2018-01-24 キッセイ薬品工業株式会社 縮合複素環誘導体の製造方法およびその製造中間体
IL241595B2 (en) 2013-03-15 2025-10-01 Abbvie Inc Composition for use in methods of treating heavy menstrual bleeding associated with uterine fibroids
AU2017309015B2 (en) 2016-08-08 2022-09-15 Kissei Pharmaceutical Co., Ltd. Administration and dosage of therapeutic agent for endometriosis
SMT202200254T1 (it) 2016-09-30 2022-07-21 Takeda Pharmaceuticals Co Metodi di trattamento di fibromi uterini ed endometriosi
EP3634418A1 (en) 2017-06-05 2020-04-15 ObsEva S.A. Gonadotropin-releasing hormone antagonist dosing regimens for the treatment of endometriosis
US11759464B2 (en) 2017-06-05 2023-09-19 Kissei Pharmaceutical Co., Ltd. Gonadotropin-releasing hormone antagonist dosing regimens for treating uterine fibroids and reducing menstrual blood loss
KR20210100623A (ko) 2018-11-07 2021-08-17 옵스에파 에스에이 에스트로겐-의존성 장애의 치료를 위한 조성물 및 방법

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Jorg B. Engel, et al., European Journal of Obstetrics & Gynecology and Reproductive Biology, 2007, 134(2), 225-232*
공개특허공보 제10-2008-0063827호*

Also Published As

Publication number Publication date
EP3634419A1 (en) 2020-04-15
FI3634419T3 (fi) 2025-05-02
EP4509173A2 (en) 2025-02-19
HUE070907T2 (hu) 2025-07-28
AU2018280741B2 (en) 2023-12-21
HRP20250390T1 (hr) 2025-05-23
ES3018358T3 (es) 2025-05-16
CA3066188A1 (en) 2018-12-13
KR20200024797A (ko) 2020-03-09
AU2024201694A1 (en) 2024-04-04
JP7292566B2 (ja) 2023-06-19
US11759464B2 (en) 2023-09-19
PL3634419T3 (pl) 2025-06-09
EP3634419B1 (en) 2025-01-29
DK3634419T3 (da) 2025-03-31
CN110996957A (zh) 2020-04-10
EA201992812A1 (ru) 2020-05-21
MX2023013582A (es) 2024-04-16
JP2020522525A (ja) 2020-07-30
JP2023078315A (ja) 2023-06-06
AU2018280741A1 (en) 2020-01-30
JP7485815B2 (ja) 2024-05-16
SG11201911599XA (en) 2020-01-30
US20240000785A1 (en) 2024-01-04
EP4509173A3 (en) 2025-06-04
PT3634419T (pt) 2025-04-04
MX2019014482A (es) 2020-08-17
US20200179390A1 (en) 2020-06-11
WO2018224497A1 (en) 2018-12-13

Similar Documents

Publication Publication Date Title
KR102884301B1 (ko) 자궁 근종을 치료하고 월경혈량을 감소시키기 위한 고나도트로핀 방출 호르몬 길항제 투약 요법
US20240293414A1 (en) Gonadotropin-releasing hormone antagonist dosing regimens for the treatment of endometriosis
EP3876943A2 (en) Compositions and methods for the treatment of estrogen-dependent disorders
KR20220045198A (ko) 에스트로겐-의존성 장애의 치료를 위한 gnrh 길항제
WO2021023877A2 (en) Compositions and methods for the treatment of estrogen-dependent disorders
EP3873465B1 (en) Compositions and methods for the treatment of adenomyosis and rectovaginal endometriosis
HK40116843A (en) Gonadotropin-releasing hormone antagonist dosing regimens for treating uterine fibroids and reducing menstrual blood loss
HK40027583A (en) Dosing regimen comprising a gonadotropin-releasing hormone antagonist for treating uterine fibroids and reducing menstrual blood loss
HK40027583B (en) Dosing regimen comprising a gonadotropin-releasing hormone antagonist for treating uterine fibroids and reducing menstrual blood loss
EA049129B1 (ru) Схемы применения антагониста гонадотропин-высвобождающего гормона для лечения миомы матки и уменьшения менструальной кровопотери
HK40059353A (en) Compositions and methods for the treatment of adenomyosis and rectovaginal endometriosis
HK40059353B (en) Compositions and methods for the treatment of adenomyosis and rectovaginal endometriosis

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

PN2301 Change of applicant

St.27 status event code: A-3-3-R10-R13-asn-PN2301

St.27 status event code: A-3-3-R10-R11-asn-PN2301

PN2301 Change of applicant

St.27 status event code: A-3-3-R10-R13-asn-PN2301

St.27 status event code: A-3-3-R10-R11-asn-PN2301

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PE0601 Decision on rejection of patent

St.27 status event code: N-2-6-B10-B15-exm-PE0601

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T13-X000 Administrative time limit extension granted

St.27 status event code: U-3-3-T10-T13-oth-X000

AMND Amendment
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PX0901 Re-examination

St.27 status event code: A-2-3-E10-E12-rex-PX0901

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

F13 Ip right granted in full following pre-grant review

Free format text: ST27 STATUS EVENT CODE: A-3-4-F10-F13-REX-PX0701 (AS PROVIDED BY THE NATIONAL OFFICE)

PX0701 Decision of registration after re-examination

St.27 status event code: A-3-4-F10-F13-rex-PX0701

F11 Ip right granted following substantive examination

Free format text: ST27 STATUS EVENT CODE: A-2-4-F10-F11-EXM-PR0701 (AS PROVIDED BY THE NATIONAL OFFICE)

PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

U12 Designation fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U12-OTH-PR1002 (AS PROVIDED BY THE NATIONAL OFFICE)

Year of fee payment: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

Q13 Ip right document published

Free format text: ST27 STATUS EVENT CODE: A-4-4-Q10-Q13-NAP-PG1601 (AS PROVIDED BY THE NATIONAL OFFICE)